Yahoo Finance Shield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)
Shield Therapeutics (LON:STX) First Half 2023 Results
Key Financial Results
Revenue: US$4.33m (up 69% from 1H 2022).
Net loss: US$12.6m (loss narrowed by 16% from 1H 2022).
US$0.025 loss per share (improved from US$0.069 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shield Therapeutics Earnings Insights
Looking ahead, revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are down 32% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Shield Therapeutics (at least 2 which make us uncomfortable), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
